Alpha-1-proteinase inhibitor, also known as Alpha 1 antitrypsin (A1AT), a circulating extracellular protein capable of inhibiting extracellular proteases, was approved by the FDA for treatment of A1AT deficiency. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.